Branched-chain amino acid-enriched elemental diet in patients with cirrhosis of the liver. A double blind crossover trial

Z Gastroenterol. 1983 Nov;21(11):644-50.

Abstract

In 14 patients with cirrhosis of the liver and portal-systemic shunts the effect of a branched-chain amino acid-enriched elemental diet on portal systemic encephalopathy, routine laboratory parameters and plasma amino acids was investigated. In addition to the standard therapy including protein restriction (40 g/day) the patients received 44 g of an amino acid-protein mixture containing 30% of branched-chain amino acids and placebo over 3 months in a crossover regimen. Plasma valine and leucine increased significantly, whereas all other amino acids, including the ratio (formula: see text), remained unchanged. The electroencephalogram, number connection test, clinical state and laboratory parameters were not influenced by therapy with branched-chain amino acids. Thus, orally administered branched-chain amino acids probably have no influence on hepatic encephalopathy but are an adequate source of nitrogen in patients with cirrhosis of the liver.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Amino Acids, Branched-Chain / administration & dosage
  • Amino Acids, Branched-Chain / therapeutic use*
  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Double-Blind Method
  • Electroencephalography
  • Female
  • Hepatic Encephalopathy / diet therapy*
  • Hepatic Encephalopathy / physiopathology
  • Humans
  • Liver Cirrhosis / blood
  • Liver Cirrhosis / diet therapy*
  • Liver Cirrhosis, Alcoholic / blood
  • Liver Cirrhosis, Alcoholic / diet therapy*
  • Male
  • Middle Aged
  • Portacaval Shunt, Surgical

Substances

  • Amino Acids, Branched-Chain